nodes	percent_of_prediction	percent_of_DWPC	metapath
Risedronate—PTGS2—ovarian follicle—ovarian cancer	0.0515	0.208	CbGeAlD
Risedronate—FDPS—myometrium—ovarian cancer	0.0189	0.0764	CbGeAlD
Risedronate—FDPS—uterine cervix—ovarian cancer	0.0147	0.0594	CbGeAlD
Risedronate—FDPS—decidua—ovarian cancer	0.014	0.0566	CbGeAlD
Risedronate—FDPS—endometrium—ovarian cancer	0.0133	0.0538	CbGeAlD
Risedronate—FDPS—gonad—ovarian cancer	0.0123	0.0499	CbGeAlD
Risedronate—FDPS—uterus—ovarian cancer	0.0122	0.0495	CbGeAlD
Risedronate—FDPS—female reproductive system—ovarian cancer	0.011	0.0445	CbGeAlD
Risedronate—FDPS—bone marrow—ovarian cancer	0.0104	0.042	CbGeAlD
Risedronate—FDPS—female gonad—ovarian cancer	0.01	0.0405	CbGeAlD
Risedronate—FDPS—vagina—ovarian cancer	0.00996	0.0403	CbGeAlD
Risedronate—FDPS—testis—ovarian cancer	0.00889	0.0359	CbGeAlD
Risedronate—PTGS2—myometrium—ovarian cancer	0.00724	0.0293	CbGeAlD
Risedronate—PTGS2—embryo—ovarian cancer	0.00696	0.0282	CbGeAlD
Risedronate—FDPS—lymph node—ovarian cancer	0.00644	0.0261	CbGeAlD
Risedronate—PTGS2—epithelium—ovarian cancer	0.00568	0.023	CbGeAlD
Risedronate—PTGS2—uterine cervix—ovarian cancer	0.00563	0.0228	CbGeAlD
Risedronate—PTGS2—endometrium—ovarian cancer	0.00509	0.0206	CbGeAlD
Risedronate—PTGS2—uterus—ovarian cancer	0.00469	0.019	CbGeAlD
Risedronate—PTGS2—female reproductive system—ovarian cancer	0.00422	0.0171	CbGeAlD
Risedronate—PTGS2—bone marrow—ovarian cancer	0.00398	0.0161	CbGeAlD
Risedronate—PTGS2—female gonad—ovarian cancer	0.00384	0.0155	CbGeAlD
Risedronate—PTGS2—vagina—ovarian cancer	0.00382	0.0154	CbGeAlD
Risedronate—PTGS2—lymph node—ovarian cancer	0.00247	0.00998	CbGeAlD
Risedronate—Immune system disorder—Docetaxel—ovarian cancer	0.000885	0.00118	CcSEcCtD
Risedronate—Loss of consciousness—Paclitaxel—ovarian cancer	0.000885	0.00118	CcSEcCtD
Risedronate—Osteoarthritis—Doxorubicin—ovarian cancer	0.000884	0.00118	CcSEcCtD
Risedronate—Pain in extremity—Doxorubicin—ovarian cancer	0.000884	0.00118	CcSEcCtD
Risedronate—Mediastinal disorder—Docetaxel—ovarian cancer	0.000884	0.00117	CcSEcCtD
Risedronate—Liver function test abnormal—Epirubicin—ovarian cancer	0.000882	0.00117	CcSEcCtD
Risedronate—Rash—Melphalan—ovarian cancer	0.000882	0.00117	CcSEcCtD
Risedronate—Dermatitis—Melphalan—ovarian cancer	0.000881	0.00117	CcSEcCtD
Risedronate—Cough—Paclitaxel—ovarian cancer	0.000879	0.00117	CcSEcCtD
Risedronate—Asthenia—Vinorelbine—ovarian cancer	0.000877	0.00116	CcSEcCtD
Risedronate—Arrhythmia—Docetaxel—ovarian cancer	0.000876	0.00116	CcSEcCtD
Risedronate—Abdominal pain upper—Epirubicin—ovarian cancer	0.000873	0.00116	CcSEcCtD
Risedronate—Hypertension—Paclitaxel—ovarian cancer	0.000869	0.00116	CcSEcCtD
Risedronate—Pruritus—Vinorelbine—ovarian cancer	0.000864	0.00115	CcSEcCtD
Risedronate—Breast disorder—Epirubicin—ovarian cancer	0.000864	0.00115	CcSEcCtD
Risedronate—Mental disorder—Docetaxel—ovarian cancer	0.000859	0.00114	CcSEcCtD
Risedronate—Chest pain—Paclitaxel—ovarian cancer	0.000857	0.00114	CcSEcCtD
Risedronate—Myalgia—Paclitaxel—ovarian cancer	0.000857	0.00114	CcSEcCtD
Risedronate—Arthralgia—Paclitaxel—ovarian cancer	0.000857	0.00114	CcSEcCtD
Risedronate—Nasopharyngitis—Epirubicin—ovarian cancer	0.000855	0.00114	CcSEcCtD
Risedronate—Anxiety—Paclitaxel—ovarian cancer	0.000854	0.00114	CcSEcCtD
Risedronate—Malnutrition—Docetaxel—ovarian cancer	0.000853	0.00113	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000851	0.00113	CcSEcCtD
Risedronate—Nausea—Topotecan—ovarian cancer	0.000848	0.00113	CcSEcCtD
Risedronate—Gastritis—Epirubicin—ovarian cancer	0.000846	0.00112	CcSEcCtD
Risedronate—Muscular weakness—Epirubicin—ovarian cancer	0.000843	0.00112	CcSEcCtD
Risedronate—Dry mouth—Paclitaxel—ovarian cancer	0.000838	0.00111	CcSEcCtD
Risedronate—Diarrhoea—Vinorelbine—ovarian cancer	0.000836	0.00111	CcSEcCtD
Risedronate—Abdominal distension—Epirubicin—ovarian cancer	0.000832	0.00111	CcSEcCtD
Risedronate—Nausea—Melphalan—ovarian cancer	0.000831	0.0011	CcSEcCtD
Risedronate—Asthma—Epirubicin—ovarian cancer	0.000826	0.0011	CcSEcCtD
Risedronate—Influenza—Epirubicin—ovarian cancer	0.000826	0.0011	CcSEcCtD
Risedronate—Back pain—Docetaxel—ovarian cancer	0.000825	0.0011	CcSEcCtD
Risedronate—Muscle spasms—Docetaxel—ovarian cancer	0.00082	0.00109	CcSEcCtD
Risedronate—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000817	0.00108	CcSEcCtD
Risedronate—Infection—Paclitaxel—ovarian cancer	0.000816	0.00108	CcSEcCtD
Risedronate—Shock—Paclitaxel—ovarian cancer	0.000808	0.00107	CcSEcCtD
Risedronate—Dizziness—Vinorelbine—ovarian cancer	0.000808	0.00107	CcSEcCtD
Risedronate—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000808	0.00107	CcSEcCtD
Risedronate—Nervous system disorder—Paclitaxel—ovarian cancer	0.000806	0.00107	CcSEcCtD
Risedronate—Angina pectoris—Epirubicin—ovarian cancer	0.000805	0.00107	CcSEcCtD
Risedronate—Breast disorder—Doxorubicin—ovarian cancer	0.000799	0.00106	CcSEcCtD
Risedronate—Skin disorder—Paclitaxel—ovarian cancer	0.000798	0.00106	CcSEcCtD
Risedronate—Bronchitis—Epirubicin—ovarian cancer	0.000794	0.00106	CcSEcCtD
Risedronate—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000791	0.00105	CcSEcCtD
Risedronate—Anaemia—Docetaxel—ovarian cancer	0.000789	0.00105	CcSEcCtD
Risedronate—Gastritis—Doxorubicin—ovarian cancer	0.000783	0.00104	CcSEcCtD
Risedronate—Muscular weakness—Doxorubicin—ovarian cancer	0.00078	0.00104	CcSEcCtD
Risedronate—Vomiting—Vinorelbine—ovarian cancer	0.000777	0.00103	CcSEcCtD
Risedronate—Rash—Vinorelbine—ovarian cancer	0.00077	0.00102	CcSEcCtD
Risedronate—Dermatitis—Vinorelbine—ovarian cancer	0.00077	0.00102	CcSEcCtD
Risedronate—Abdominal distension—Doxorubicin—ovarian cancer	0.00077	0.00102	CcSEcCtD
Risedronate—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000768	0.00102	CcSEcCtD
Risedronate—Headache—Vinorelbine—ovarian cancer	0.000765	0.00102	CcSEcCtD
Risedronate—Syncope—Docetaxel—ovarian cancer	0.000765	0.00102	CcSEcCtD
Risedronate—Asthma—Doxorubicin—ovarian cancer	0.000764	0.00102	CcSEcCtD
Risedronate—Influenza—Doxorubicin—ovarian cancer	0.000764	0.00102	CcSEcCtD
Risedronate—Loss of consciousness—Docetaxel—ovarian cancer	0.00075	0.000997	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000749	0.000995	CcSEcCtD
Risedronate—Cough—Docetaxel—ovarian cancer	0.000745	0.00099	CcSEcCtD
Risedronate—Angina pectoris—Doxorubicin—ovarian cancer	0.000745	0.000989	CcSEcCtD
Risedronate—Insomnia—Paclitaxel—ovarian cancer	0.000743	0.000988	CcSEcCtD
Risedronate—Pneumonia—Epirubicin—ovarian cancer	0.000741	0.000984	CcSEcCtD
Risedronate—Paraesthesia—Paclitaxel—ovarian cancer	0.000738	0.00098	CcSEcCtD
Risedronate—Hypertension—Docetaxel—ovarian cancer	0.000737	0.000979	CcSEcCtD
Risedronate—Infestation NOS—Epirubicin—ovarian cancer	0.000737	0.000979	CcSEcCtD
Risedronate—Infestation—Epirubicin—ovarian cancer	0.000737	0.000979	CcSEcCtD
Risedronate—Bronchitis—Doxorubicin—ovarian cancer	0.000735	0.000977	CcSEcCtD
Risedronate—Dyspnoea—Paclitaxel—ovarian cancer	0.000733	0.000973	CcSEcCtD
Risedronate—Chest pain—Docetaxel—ovarian cancer	0.000727	0.000965	CcSEcCtD
Risedronate—Myalgia—Docetaxel—ovarian cancer	0.000727	0.000965	CcSEcCtD
Risedronate—Arthralgia—Docetaxel—ovarian cancer	0.000727	0.000965	CcSEcCtD
Risedronate—Nausea—Vinorelbine—ovarian cancer	0.000726	0.000964	CcSEcCtD
Risedronate—Dyspepsia—Paclitaxel—ovarian cancer	0.000723	0.000961	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000722	0.000959	CcSEcCtD
Risedronate—Conjunctivitis—Epirubicin—ovarian cancer	0.000716	0.000951	CcSEcCtD
Risedronate—Urinary tract infection—Epirubicin—ovarian cancer	0.000716	0.000951	CcSEcCtD
Risedronate—Dry mouth—Docetaxel—ovarian cancer	0.000711	0.000944	CcSEcCtD
Risedronate—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.00071	0.000944	CcSEcCtD
Risedronate—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000709	0.000943	CcSEcCtD
Risedronate—Fatigue—Paclitaxel—ovarian cancer	0.000708	0.000941	CcSEcCtD
Risedronate—Constipation—Paclitaxel—ovarian cancer	0.000703	0.000934	CcSEcCtD
Risedronate—Pain—Paclitaxel—ovarian cancer	0.000703	0.000934	CcSEcCtD
Risedronate—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000697	0.000926	CcSEcCtD
Risedronate—Infection—Docetaxel—ovarian cancer	0.000692	0.000919	CcSEcCtD
Risedronate—Sinusitis—Epirubicin—ovarian cancer	0.000691	0.000918	CcSEcCtD
Risedronate—Pneumonia—Doxorubicin—ovarian cancer	0.000685	0.000911	CcSEcCtD
Risedronate—Shock—Docetaxel—ovarian cancer	0.000685	0.000911	CcSEcCtD
Risedronate—Nervous system disorder—Docetaxel—ovarian cancer	0.000683	0.000908	CcSEcCtD
Risedronate—Infestation NOS—Doxorubicin—ovarian cancer	0.000682	0.000906	CcSEcCtD
Risedronate—Infestation—Doxorubicin—ovarian cancer	0.000682	0.000906	CcSEcCtD
Risedronate—Skin disorder—Docetaxel—ovarian cancer	0.000677	0.000899	CcSEcCtD
Risedronate—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000672	0.000893	CcSEcCtD
Risedronate—Haemoglobin—Epirubicin—ovarian cancer	0.000665	0.000883	CcSEcCtD
Risedronate—Rhinitis—Epirubicin—ovarian cancer	0.000663	0.000881	CcSEcCtD
Risedronate—Conjunctivitis—Doxorubicin—ovarian cancer	0.000662	0.00088	CcSEcCtD
Risedronate—Urinary tract infection—Doxorubicin—ovarian cancer	0.000662	0.00088	CcSEcCtD
Risedronate—Haemorrhage—Epirubicin—ovarian cancer	0.000661	0.000879	CcSEcCtD
Risedronate—Pharyngitis—Epirubicin—ovarian cancer	0.000656	0.000872	CcSEcCtD
Risedronate—Urinary tract disorder—Epirubicin—ovarian cancer	0.000653	0.000868	CcSEcCtD
Risedronate—Urticaria—Paclitaxel—ovarian cancer	0.000653	0.000867	CcSEcCtD
Risedronate—Oedema peripheral—Epirubicin—ovarian cancer	0.000651	0.000866	CcSEcCtD
Risedronate—Connective tissue disorder—Epirubicin—ovarian cancer	0.00065	0.000863	CcSEcCtD
Risedronate—Abdominal pain—Paclitaxel—ovarian cancer	0.00065	0.000863	CcSEcCtD
Risedronate—Body temperature increased—Paclitaxel—ovarian cancer	0.00065	0.000863	CcSEcCtD
Risedronate—Urethral disorder—Epirubicin—ovarian cancer	0.000648	0.000861	CcSEcCtD
Risedronate—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000645	0.000856	CcSEcCtD
Risedronate—Sinusitis—Doxorubicin—ovarian cancer	0.000639	0.00085	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000635	0.000843	CcSEcCtD
Risedronate—Insomnia—Docetaxel—ovarian cancer	0.00063	0.000837	CcSEcCtD
Risedronate—Paraesthesia—Docetaxel—ovarian cancer	0.000625	0.000831	CcSEcCtD
Risedronate—Dyspnoea—Docetaxel—ovarian cancer	0.000621	0.000825	CcSEcCtD
Risedronate—Eye disorder—Epirubicin—ovarian cancer	0.000618	0.000821	CcSEcCtD
Risedronate—Tinnitus—Epirubicin—ovarian cancer	0.000617	0.000819	CcSEcCtD
Risedronate—Haemoglobin—Doxorubicin—ovarian cancer	0.000615	0.000817	CcSEcCtD
Risedronate—Cardiac disorder—Epirubicin—ovarian cancer	0.000614	0.000815	CcSEcCtD
Risedronate—Rhinitis—Doxorubicin—ovarian cancer	0.000613	0.000815	CcSEcCtD
Risedronate—Dyspepsia—Docetaxel—ovarian cancer	0.000613	0.000815	CcSEcCtD
Risedronate—Haemorrhage—Doxorubicin—ovarian cancer	0.000612	0.000813	CcSEcCtD
Risedronate—Pharyngitis—Doxorubicin—ovarian cancer	0.000607	0.000807	CcSEcCtD
Risedronate—Hypersensitivity—Paclitaxel—ovarian cancer	0.000605	0.000804	CcSEcCtD
Risedronate—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000604	0.000803	CcSEcCtD
Risedronate—Oedema peripheral—Doxorubicin—ovarian cancer	0.000603	0.000801	CcSEcCtD
Risedronate—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000601	0.000799	CcSEcCtD
Risedronate—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000601	0.000799	CcSEcCtD
Risedronate—Fatigue—Docetaxel—ovarian cancer	0.0006	0.000798	CcSEcCtD
Risedronate—Angiopathy—Epirubicin—ovarian cancer	0.0006	0.000797	CcSEcCtD
Risedronate—Urethral disorder—Doxorubicin—ovarian cancer	0.0006	0.000797	CcSEcCtD
Risedronate—Immune system disorder—Epirubicin—ovarian cancer	0.000597	0.000794	CcSEcCtD
Risedronate—Mediastinal disorder—Epirubicin—ovarian cancer	0.000596	0.000792	CcSEcCtD
Risedronate—Constipation—Docetaxel—ovarian cancer	0.000596	0.000791	CcSEcCtD
Risedronate—Pain—Docetaxel—ovarian cancer	0.000596	0.000791	CcSEcCtD
Risedronate—Arrhythmia—Epirubicin—ovarian cancer	0.000591	0.000785	CcSEcCtD
Risedronate—Asthenia—Paclitaxel—ovarian cancer	0.00059	0.000783	CcSEcCtD
Risedronate—Pruritus—Paclitaxel—ovarian cancer	0.000581	0.000772	CcSEcCtD
Risedronate—Mental disorder—Epirubicin—ovarian cancer	0.000579	0.00077	CcSEcCtD
Risedronate—Malnutrition—Epirubicin—ovarian cancer	0.000576	0.000765	CcSEcCtD
Risedronate—Eye disorder—Doxorubicin—ovarian cancer	0.000572	0.00076	CcSEcCtD
Risedronate—Tinnitus—Doxorubicin—ovarian cancer	0.00057	0.000758	CcSEcCtD
Risedronate—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00057	0.000757	CcSEcCtD
Risedronate—Cardiac disorder—Doxorubicin—ovarian cancer	0.000568	0.000754	CcSEcCtD
Risedronate—Flatulence—Epirubicin—ovarian cancer	0.000567	0.000754	CcSEcCtD
Risedronate—Diarrhoea—Paclitaxel—ovarian cancer	0.000562	0.000747	CcSEcCtD
Risedronate—Back pain—Epirubicin—ovarian cancer	0.000557	0.00074	CcSEcCtD
Risedronate—Angiopathy—Doxorubicin—ovarian cancer	0.000555	0.000738	CcSEcCtD
Risedronate—Muscle spasms—Epirubicin—ovarian cancer	0.000553	0.000735	CcSEcCtD
Risedronate—Immune system disorder—Doxorubicin—ovarian cancer	0.000553	0.000734	CcSEcCtD
Risedronate—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000551	0.000733	CcSEcCtD
Risedronate—Abdominal pain—Docetaxel—ovarian cancer	0.000551	0.000732	CcSEcCtD
Risedronate—Body temperature increased—Docetaxel—ovarian cancer	0.000551	0.000732	CcSEcCtD
Risedronate—Arrhythmia—Doxorubicin—ovarian cancer	0.000547	0.000726	CcSEcCtD
Risedronate—Dizziness—Paclitaxel—ovarian cancer	0.000543	0.000722	CcSEcCtD
Risedronate—Mental disorder—Doxorubicin—ovarian cancer	0.000536	0.000712	CcSEcCtD
Risedronate—Malnutrition—Doxorubicin—ovarian cancer	0.000533	0.000708	CcSEcCtD
Risedronate—Anaemia—Epirubicin—ovarian cancer	0.000532	0.000707	CcSEcCtD
Risedronate—Flatulence—Doxorubicin—ovarian cancer	0.000525	0.000697	CcSEcCtD
Risedronate—Vomiting—Paclitaxel—ovarian cancer	0.000522	0.000694	CcSEcCtD
Risedronate—Rash—Paclitaxel—ovarian cancer	0.000518	0.000688	CcSEcCtD
Risedronate—Dermatitis—Paclitaxel—ovarian cancer	0.000518	0.000688	CcSEcCtD
Risedronate—Vertigo—Epirubicin—ovarian cancer	0.000517	0.000687	CcSEcCtD
Risedronate—Syncope—Epirubicin—ovarian cancer	0.000516	0.000686	CcSEcCtD
Risedronate—Back pain—Doxorubicin—ovarian cancer	0.000515	0.000685	CcSEcCtD
Risedronate—Headache—Paclitaxel—ovarian cancer	0.000515	0.000684	CcSEcCtD
Risedronate—Hypersensitivity—Docetaxel—ovarian cancer	0.000513	0.000682	CcSEcCtD
Risedronate—Muscle spasms—Doxorubicin—ovarian cancer	0.000512	0.00068	CcSEcCtD
Risedronate—Loss of consciousness—Epirubicin—ovarian cancer	0.000506	0.000672	CcSEcCtD
Risedronate—Cough—Epirubicin—ovarian cancer	0.000502	0.000667	CcSEcCtD
Risedronate—Asthenia—Docetaxel—ovarian cancer	0.0005	0.000664	CcSEcCtD
Risedronate—Hypertension—Epirubicin—ovarian cancer	0.000497	0.00066	CcSEcCtD
Risedronate—Pruritus—Docetaxel—ovarian cancer	0.000493	0.000655	CcSEcCtD
Risedronate—Anaemia—Doxorubicin—ovarian cancer	0.000492	0.000654	CcSEcCtD
Risedronate—Arthralgia—Epirubicin—ovarian cancer	0.00049	0.000651	CcSEcCtD
Risedronate—Myalgia—Epirubicin—ovarian cancer	0.00049	0.000651	CcSEcCtD
Risedronate—Chest pain—Epirubicin—ovarian cancer	0.00049	0.000651	CcSEcCtD
Risedronate—Anxiety—Epirubicin—ovarian cancer	0.000488	0.000649	CcSEcCtD
Risedronate—Nausea—Paclitaxel—ovarian cancer	0.000488	0.000649	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000487	0.000647	CcSEcCtD
Risedronate—Dry mouth—Epirubicin—ovarian cancer	0.000479	0.000637	CcSEcCtD
Risedronate—Vertigo—Doxorubicin—ovarian cancer	0.000479	0.000636	CcSEcCtD
Risedronate—Syncope—Doxorubicin—ovarian cancer	0.000478	0.000635	CcSEcCtD
Risedronate—Diarrhoea—Docetaxel—ovarian cancer	0.000477	0.000633	CcSEcCtD
Risedronate—Loss of consciousness—Doxorubicin—ovarian cancer	0.000468	0.000622	CcSEcCtD
Risedronate—Infection—Epirubicin—ovarian cancer	0.000467	0.00062	CcSEcCtD
Risedronate—Cough—Doxorubicin—ovarian cancer	0.000465	0.000618	CcSEcCtD
Risedronate—Shock—Epirubicin—ovarian cancer	0.000462	0.000614	CcSEcCtD
Risedronate—Nervous system disorder—Epirubicin—ovarian cancer	0.000461	0.000612	CcSEcCtD
Risedronate—Dizziness—Docetaxel—ovarian cancer	0.000461	0.000612	CcSEcCtD
Risedronate—Hypertension—Doxorubicin—ovarian cancer	0.00046	0.000611	CcSEcCtD
Risedronate—Skin disorder—Epirubicin—ovarian cancer	0.000456	0.000606	CcSEcCtD
Risedronate—Arthralgia—Doxorubicin—ovarian cancer	0.000453	0.000603	CcSEcCtD
Risedronate—Myalgia—Doxorubicin—ovarian cancer	0.000453	0.000603	CcSEcCtD
Risedronate—Chest pain—Doxorubicin—ovarian cancer	0.000453	0.000603	CcSEcCtD
Risedronate—Anxiety—Doxorubicin—ovarian cancer	0.000452	0.0006	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.00045	0.000598	CcSEcCtD
Risedronate—Dry mouth—Doxorubicin—ovarian cancer	0.000443	0.000589	CcSEcCtD
Risedronate—Vomiting—Docetaxel—ovarian cancer	0.000443	0.000588	CcSEcCtD
Risedronate—Rash—Docetaxel—ovarian cancer	0.000439	0.000584	CcSEcCtD
Risedronate—Dermatitis—Docetaxel—ovarian cancer	0.000439	0.000583	CcSEcCtD
Risedronate—Headache—Docetaxel—ovarian cancer	0.000436	0.00058	CcSEcCtD
Risedronate—Infection—Doxorubicin—ovarian cancer	0.000432	0.000574	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000428	0.000569	CcSEcCtD
Risedronate—Shock—Doxorubicin—ovarian cancer	0.000428	0.000568	CcSEcCtD
Risedronate—Nervous system disorder—Doxorubicin—ovarian cancer	0.000426	0.000566	CcSEcCtD
Risedronate—Insomnia—Epirubicin—ovarian cancer	0.000425	0.000565	CcSEcCtD
Risedronate—Skin disorder—Doxorubicin—ovarian cancer	0.000422	0.000561	CcSEcCtD
Risedronate—Paraesthesia—Epirubicin—ovarian cancer	0.000422	0.000561	CcSEcCtD
Risedronate—Dyspnoea—Epirubicin—ovarian cancer	0.000419	0.000557	CcSEcCtD
Risedronate—Nausea—Docetaxel—ovarian cancer	0.000414	0.00055	CcSEcCtD
Risedronate—Dyspepsia—Epirubicin—ovarian cancer	0.000414	0.000549	CcSEcCtD
Risedronate—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000406	0.000539	CcSEcCtD
Risedronate—Fatigue—Epirubicin—ovarian cancer	0.000405	0.000538	CcSEcCtD
Risedronate—Pain—Epirubicin—ovarian cancer	0.000402	0.000534	CcSEcCtD
Risedronate—Constipation—Epirubicin—ovarian cancer	0.000402	0.000534	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000396	0.000526	CcSEcCtD
Risedronate—Insomnia—Doxorubicin—ovarian cancer	0.000393	0.000522	CcSEcCtD
Risedronate—Paraesthesia—Doxorubicin—ovarian cancer	0.00039	0.000519	CcSEcCtD
Risedronate—Dyspnoea—Doxorubicin—ovarian cancer	0.000388	0.000515	CcSEcCtD
Risedronate—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000384	0.00051	CcSEcCtD
Risedronate—Dyspepsia—Doxorubicin—ovarian cancer	0.000383	0.000508	CcSEcCtD
Risedronate—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000375	0.000499	CcSEcCtD
Risedronate—Fatigue—Doxorubicin—ovarian cancer	0.000375	0.000498	CcSEcCtD
Risedronate—Urticaria—Epirubicin—ovarian cancer	0.000373	0.000496	CcSEcCtD
Risedronate—Constipation—Doxorubicin—ovarian cancer	0.000372	0.000494	CcSEcCtD
Risedronate—Pain—Doxorubicin—ovarian cancer	0.000372	0.000494	CcSEcCtD
Risedronate—Abdominal pain—Epirubicin—ovarian cancer	0.000371	0.000493	CcSEcCtD
Risedronate—Body temperature increased—Epirubicin—ovarian cancer	0.000371	0.000493	CcSEcCtD
Risedronate—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000355	0.000472	CcSEcCtD
Risedronate—Hypersensitivity—Epirubicin—ovarian cancer	0.000346	0.00046	CcSEcCtD
Risedronate—Urticaria—Doxorubicin—ovarian cancer	0.000345	0.000459	CcSEcCtD
Risedronate—Body temperature increased—Doxorubicin—ovarian cancer	0.000344	0.000457	CcSEcCtD
Risedronate—Abdominal pain—Doxorubicin—ovarian cancer	0.000344	0.000457	CcSEcCtD
Risedronate—Asthenia—Epirubicin—ovarian cancer	0.000337	0.000448	CcSEcCtD
Risedronate—Pruritus—Epirubicin—ovarian cancer	0.000332	0.000442	CcSEcCtD
Risedronate—Diarrhoea—Epirubicin—ovarian cancer	0.000321	0.000427	CcSEcCtD
Risedronate—Hypersensitivity—Doxorubicin—ovarian cancer	0.00032	0.000426	CcSEcCtD
Risedronate—Asthenia—Doxorubicin—ovarian cancer	0.000312	0.000414	CcSEcCtD
Risedronate—Dizziness—Epirubicin—ovarian cancer	0.000311	0.000413	CcSEcCtD
Risedronate—Pruritus—Doxorubicin—ovarian cancer	0.000308	0.000409	CcSEcCtD
Risedronate—Vomiting—Epirubicin—ovarian cancer	0.000299	0.000397	CcSEcCtD
Risedronate—Diarrhoea—Doxorubicin—ovarian cancer	0.000297	0.000395	CcSEcCtD
Risedronate—Rash—Epirubicin—ovarian cancer	0.000296	0.000394	CcSEcCtD
Risedronate—Dermatitis—Epirubicin—ovarian cancer	0.000296	0.000393	CcSEcCtD
Risedronate—Headache—Epirubicin—ovarian cancer	0.000294	0.000391	CcSEcCtD
Risedronate—Dizziness—Doxorubicin—ovarian cancer	0.000287	0.000382	CcSEcCtD
Risedronate—Nausea—Epirubicin—ovarian cancer	0.000279	0.000371	CcSEcCtD
Risedronate—Vomiting—Doxorubicin—ovarian cancer	0.000276	0.000367	CcSEcCtD
Risedronate—Rash—Doxorubicin—ovarian cancer	0.000274	0.000364	CcSEcCtD
Risedronate—Dermatitis—Doxorubicin—ovarian cancer	0.000274	0.000364	CcSEcCtD
Risedronate—Headache—Doxorubicin—ovarian cancer	0.000272	0.000362	CcSEcCtD
Risedronate—Nausea—Doxorubicin—ovarian cancer	0.000258	0.000343	CcSEcCtD
Risedronate—FDPS—Activation of gene expression by SREBF (SREBP)—FASN—ovarian cancer	1.27e-05	0.0846	CbGpPWpGaD
Risedronate—PTGS2—Prostaglandin Synthesis and Regulation—ANXA3—ovarian cancer	1.24e-05	0.0828	CbGpPWpGaD
Risedronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—FASN—ovarian cancer	1.01e-05	0.0675	CbGpPWpGaD
Risedronate—FDPS—SREBP signalling—FASN—ovarian cancer	8.19e-06	0.0547	CbGpPWpGaD
Risedronate—FDPS—SREBP signalling—MTOR—ovarian cancer	3.39e-06	0.0226	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	2.77e-06	0.0185	CbGpPWpGaD
Risedronate—PTGS2—Overview of nanoparticle effects—PIK3CD—ovarian cancer	2.62e-06	0.0175	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—ovarian cancer	2.47e-06	0.0165	CbGpPWpGaD
Risedronate—PTGS2—Arachidonic acid metabolism—CYP1B1—ovarian cancer	2.31e-06	0.0154	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	2.23e-06	0.0149	CbGpPWpGaD
Risedronate—PTGS2—Overview of nanoparticle effects—CXCL8—ovarian cancer	2.19e-06	0.0146	CbGpPWpGaD
Risedronate—FDPS—Metabolism—NME2—ovarian cancer	2.19e-06	0.0146	CbGpPWpGaD
Risedronate—FDPS—SREBP signalling—PIK3CA—ovarian cancer	2.07e-06	0.0138	CbGpPWpGaD
Risedronate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—ovarian cancer	2.04e-06	0.0136	CbGpPWpGaD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—ovarian cancer	1.93e-06	0.0129	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.86e-06	0.0124	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	1.82e-06	0.0121	CbGpPWpGaD
Risedronate—PTGS2—S1P1 pathway—VEGFA—ovarian cancer	1.78e-06	0.0119	CbGpPWpGaD
Risedronate—FDPS—SREBP signalling—AKT1—ovarian cancer	1.69e-06	0.0113	CbGpPWpGaD
Risedronate—PTGS2—S1P1 pathway—MAPK3—ovarian cancer	1.68e-06	0.0112	CbGpPWpGaD
Risedronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—FASN—ovarian cancer	1.63e-06	0.0109	CbGpPWpGaD
Risedronate—PTGS2—S1P1 pathway—MAPK1—ovarian cancer	1.6e-06	0.0107	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—ESR1—ovarian cancer	1.55e-06	0.0104	CbGpPWpGaD
Risedronate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—ovarian cancer	1.55e-06	0.0103	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.51e-06	0.0101	CbGpPWpGaD
Risedronate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—ovarian cancer	1.49e-06	0.00997	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CYTB—ovarian cancer	1.41e-06	0.00942	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.38e-06	0.00921	CbGpPWpGaD
Risedronate—PTGS2—Selenium Micronutrient Network—SOD1—ovarian cancer	1.31e-06	0.00875	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—GADD45A—ovarian cancer	1.28e-06	0.00852	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PPP1CC—ovarian cancer	1.23e-06	0.00823	CbGpPWpGaD
Risedronate—FDPS—Metabolism—BRIP1—ovarian cancer	1.23e-06	0.00823	CbGpPWpGaD
Risedronate—PTGS2—Overview of nanoparticle effects—IL6—ovarian cancer	1.23e-06	0.00822	CbGpPWpGaD
Risedronate—PTGS2—Selenium Micronutrient Network—SOD2—ovarian cancer	1.18e-06	0.00788	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—ovarian cancer	1.05e-06	0.00704	CbGpPWpGaD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—ovarian cancer	1.01e-06	0.00674	CbGpPWpGaD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—ovarian cancer	9.67e-07	0.00645	CbGpPWpGaD
Risedronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—ovarian cancer	9.65e-07	0.00645	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	8.99e-07	0.006	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—ovarian cancer	8.77e-07	0.00586	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	8.68e-07	0.0058	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—ovarian cancer	8.66e-07	0.00578	CbGpPWpGaD
Risedronate—FDPS—Metabolism—YAP1—ovarian cancer	8.27e-07	0.00552	CbGpPWpGaD
Risedronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—ovarian cancer	8.25e-07	0.00551	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.19e-07	0.00547	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—MYC—ovarian cancer	8.07e-07	0.00539	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	7.94e-07	0.0053	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—ovarian cancer	7.89e-07	0.00527	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—ovarian cancer	7.89e-07	0.00527	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—TLR4—ovarian cancer	7.49e-07	0.005	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—ovarian cancer	7.46e-07	0.00498	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	7.44e-07	0.00496	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.2e-07	0.0048	CbGpPWpGaD
Risedronate—PTGS2—Disease—HSD17B6—ovarian cancer	6.85e-07	0.00457	CbGpPWpGaD
Risedronate—FDPS—Metabolism—FASN—ovarian cancer	6.74e-07	0.0045	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	6.73e-07	0.00449	CbGpPWpGaD
Risedronate—FDPS—Metabolism—SLC5A5—ovarian cancer	6.63e-07	0.00443	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	6.63e-07	0.00443	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—CDKN1B—ovarian cancer	6.51e-07	0.00435	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	6.51e-07	0.00435	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	6.51e-07	0.00435	CbGpPWpGaD
Risedronate—FDPS—Metabolism—SLC2A1—ovarian cancer	6.41e-07	0.00428	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	6.4e-07	0.00427	CbGpPWpGaD
Risedronate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—ovarian cancer	6.34e-07	0.00423	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.27e-07	0.00419	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—CCND1—ovarian cancer	6.21e-07	0.00415	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CYP1B1—ovarian cancer	6.14e-07	0.0041	CbGpPWpGaD
Risedronate—PTGS2—Disease—CHMP4C—ovarian cancer	5.47e-07	0.00365	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PPP2R1A—ovarian cancer	5.45e-07	0.00364	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.42e-07	0.00362	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—NRAS—ovarian cancer	5.35e-07	0.00357	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NME2—ovarian cancer	5.24e-07	0.0035	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—CXCL8—ovarian cancer	5.08e-07	0.00339	CbGpPWpGaD
Risedronate—FDPS—Metabolism—ABCB1—ovarian cancer	5.06e-07	0.00338	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—MYC—ovarian cancer	4.98e-07	0.00333	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	4.97e-07	0.00332	CbGpPWpGaD
Risedronate—FDPS—Metabolism—TYMS—ovarian cancer	4.97e-07	0.00332	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—CDKN1B—ovarian cancer	4.96e-07	0.00331	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—CASP3—ovarian cancer	4.86e-07	0.00325	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—IL2—ovarian cancer	4.86e-07	0.00324	CbGpPWpGaD
Risedronate—PTGS2—Disease—BCL9—ovarian cancer	4.75e-07	0.00317	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—CCND1—ovarian cancer	4.73e-07	0.00316	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	4.7e-07	0.00313	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—KRAS—ovarian cancer	4.61e-07	0.00307	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—MMP9—ovarian cancer	4.6e-07	0.00307	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	4.45e-07	0.00297	CbGpPWpGaD
Risedronate—FDPS—Metabolism—CAV1—ovarian cancer	4e-07	0.00267	CbGpPWpGaD
Risedronate—PTGS2—C-MYB transcription factor network—HRAS—ovarian cancer	3.91e-07	0.00261	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—MAPK3—ovarian cancer	3.9e-07	0.00261	CbGpPWpGaD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.82e-07	0.00255	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—MYC—ovarian cancer	3.8e-07	0.00254	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—MAPK1—ovarian cancer	3.72e-07	0.00248	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—EGFR—ovarian cancer	3.71e-07	0.00248	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	3.65e-07	0.00243	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CG—ovarian cancer	3.65e-07	0.00243	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	3.63e-07	0.00242	CbGpPWpGaD
Risedronate—PTGS2—Selenium Micronutrient Network—IL6—ovarian cancer	3.61e-07	0.00241	CbGpPWpGaD
Risedronate—PTGS2—Disease—PPP1CC—ovarian cancer	3.53e-07	0.00235	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYTB—ovarian cancer	3.38e-07	0.00226	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	3.38e-07	0.00225	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	3.31e-07	0.00221	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	3.3e-07	0.00221	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	3.22e-07	0.00215	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CD—ovarian cancer	3.2e-07	0.00214	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	3.19e-07	0.00213	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—TP53—ovarian cancer	3.12e-07	0.00208	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	3.11e-07	0.00208	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—BRIP1—ovarian cancer	2.95e-07	0.00197	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PPP1CC—ovarian cancer	2.95e-07	0.00197	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—IL6—ovarian cancer	2.85e-07	0.00191	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.81e-07	0.00187	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CB—ovarian cancer	2.79e-07	0.00186	CbGpPWpGaD
Risedronate—PTGS2—Disease—HDAC6—ovarian cancer	2.67e-07	0.00178	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.66e-07	0.00177	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.58e-07	0.00172	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.53e-07	0.00169	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.53e-07	0.00169	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PTEN—ovarian cancer	2.41e-07	0.00161	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.39e-07	0.00159	CbGpPWpGaD
Risedronate—PTGS2—Disease—XIAP—ovarian cancer	2.32e-07	0.00155	CbGpPWpGaD
Risedronate—PTGS2—Disease—SMARCA4—ovarian cancer	2.26e-07	0.00151	CbGpPWpGaD
Risedronate—PTGS2—Disease—EREG—ovarian cancer	2.2e-07	0.00147	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.19e-07	0.00146	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.15e-07	0.00144	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.12e-07	0.00142	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—YAP1—ovarian cancer	1.98e-07	0.00132	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.96e-07	0.00131	CbGpPWpGaD
Risedronate—PTGS2—Disease—FASN—ovarian cancer	1.93e-07	0.00129	CbGpPWpGaD
Risedronate—PTGS2—Disease—PARP1—ovarian cancer	1.92e-07	0.00128	CbGpPWpGaD
Risedronate—PTGS2—Disease—SLC2A1—ovarian cancer	1.83e-07	0.00122	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.79e-07	0.0012	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.72e-07	0.00115	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CA—ovarian cancer	1.7e-07	0.00114	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—FASN—ovarian cancer	1.62e-07	0.00108	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SLC5A5—ovarian cancer	1.59e-07	0.00106	CbGpPWpGaD
Risedronate—PTGS2—Disease—PPP2R1A—ovarian cancer	1.56e-07	0.00104	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SLC2A1—ovarian cancer	1.53e-07	0.00102	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.5e-07	0.001	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP1B1—ovarian cancer	1.47e-07	0.000982	CbGpPWpGaD
Risedronate—FDPS—Metabolism—AKT1—ovarian cancer	1.39e-07	0.000929	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PPP2R1A—ovarian cancer	1.3e-07	0.000871	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.3e-07	0.000867	CbGpPWpGaD
Risedronate—PTGS2—Disease—TERT—ovarian cancer	1.24e-07	0.000826	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ABCB1—ovarian cancer	1.21e-07	0.000809	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—TYMS—ovarian cancer	1.19e-07	0.000794	CbGpPWpGaD
Risedronate—PTGS2—Disease—CAV1—ovarian cancer	1.14e-07	0.000764	CbGpPWpGaD
Risedronate—PTGS2—Disease—IL6ST—ovarian cancer	1.09e-07	0.000724	CbGpPWpGaD
Risedronate—PTGS2—Disease—APC—ovarian cancer	1.04e-07	0.000696	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CAV1—ovarian cancer	9.59e-08	0.00064	CbGpPWpGaD
Risedronate—PTGS2—Disease—PIK3CD—ovarian cancer	9.17e-08	0.000612	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	9.16e-08	0.000611	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CG—ovarian cancer	8.73e-08	0.000583	CbGpPWpGaD
Risedronate—PTGS2—Disease—ERBB2—ovarian cancer	8.1e-08	0.00054	CbGpPWpGaD
Risedronate—PTGS2—Disease—MTOR—ovarian cancer	7.99e-08	0.000533	CbGpPWpGaD
Risedronate—PTGS2—Disease—PIK3CB—ovarian cancer	7.99e-08	0.000533	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CD—ovarian cancer	7.68e-08	0.000512	CbGpPWpGaD
Risedronate—PTGS2—Disease—CDKN1B—ovarian cancer	7.5e-08	0.000501	CbGpPWpGaD
Risedronate—PTGS2—Disease—CTNNB1—ovarian cancer	7.08e-08	0.000473	CbGpPWpGaD
Risedronate—PTGS2—Disease—PTEN—ovarian cancer	6.9e-08	0.000461	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CB—ovarian cancer	6.69e-08	0.000447	CbGpPWpGaD
Risedronate—PTGS2—Disease—STAT3—ovarian cancer	6.17e-08	0.000412	CbGpPWpGaD
Risedronate—PTGS2—Disease—NRAS—ovarian cancer	6.16e-08	0.000411	CbGpPWpGaD
Risedronate—PTGS2—Disease—MAPK3—ovarian cancer	5.9e-08	0.000394	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PTEN—ovarian cancer	5.78e-08	0.000386	CbGpPWpGaD
Risedronate—PTGS2—Disease—MYC—ovarian cancer	5.74e-08	0.000383	CbGpPWpGaD
Risedronate—PTGS2—Disease—MAPK1—ovarian cancer	5.61e-08	0.000375	CbGpPWpGaD
Risedronate—PTGS2—Disease—EGFR—ovarian cancer	5.61e-08	0.000375	CbGpPWpGaD
Risedronate—PTGS2—Disease—KRAS—ovarian cancer	5.3e-08	0.000354	CbGpPWpGaD
Risedronate—PTGS2—Disease—PIK3CA—ovarian cancer	4.87e-08	0.000325	CbGpPWpGaD
Risedronate—PTGS2—Disease—HRAS—ovarian cancer	4.51e-08	0.000301	CbGpPWpGaD
Risedronate—PTGS2—Disease—IL6—ovarian cancer	4.31e-08	0.000288	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CA—ovarian cancer	4.08e-08	0.000272	CbGpPWpGaD
Risedronate—PTGS2—Disease—AKT1—ovarian cancer	3.98e-08	0.000266	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—AKT1—ovarian cancer	3.33e-08	0.000222	CbGpPWpGaD
